drugset / Trial / NCT00649064

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

NCT00649064

Phase 4 Completed 46 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if differences exist in outcome in patients with schizophrenia or schizoaffective disorder who were switched from other antipsychotics to ziprasidone.

Timeline

Start
2003-12
Primary completion
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg
Subject Ziprasidone Small molecule 80 mg